J&J seeks expanded approvals for paediatric HIV-1 therapy
Drug ApprovalClinical Study
Preview
Source: Pharmaceutical Technology
Johnson & Johnson (J&J) has filed a supplemental new drug application (sNDA) with the US Food and Drug Administration (FDA) seeking expanded approval for the use of its HIV-1 therapy, PREZCOBIX (darunavir/cobicistat), in children aged six years and above.
Recommended Buyer's Guides
Preview
Source: Pharmaceutical Technology
Buyer's Guide
Leading Guide to Compliance Software for the Pharmaceutical Industry
Preview
Source: Pharmaceutical Technology
Buyer's Guide
Top Guide for Drug Delivery Systems
Approval is being sought for PREZCOBIX use in paediatric patients weighing a minimum of 25kg.
In Europe, the company has submitted applications to the European Medicines Agency for the paediatric use of the medication, marketed as REZOLSTA.
A new paediatric formulation has been developed, featuring a lower dose tablet (darunavir 675mg/cobicistat 150mg) making it easier for children to swallow.
See Also:The tiny pills that may send shockwaves across immunology
Preview
Source: Pharmaceutical Technology
Roche’s PI3K inhibitor secures breakthrough status in breast cancer
Preview
Source: Pharmaceutical Technology
The applications are supported by data from a clinical study, sponsored by Janssen Research & Development (R&D), which indicated that the new combination tablet is bioequivalent to the individual doses of darunavir and cobicistat.
A Phase II/III clinical trial by Gilead Sciences has established the efficacy, safety and tolerability of cobicistat-boosted darunavir in treating younger children with HIV-1.
PREZCOBIX/REZOLSTA combines darunavir, an HIV-1 protease inhibitorHIV-1 protease inhibitor, with cobicistat, a CYP3A inhibitor that enhances the pharmacokinetics of the therapy, allowing for once-a-day dosing.
The therapy is currently approved for use in adults and adolescents weighing a minimum of 40kg without resistance mutations to darunavir.
Darunavir is marketed by Janssen Products as PREZISTA in the US, and cobicistat, developed by Gilead Sciences, is sold as TYBOST.
Johnson & Johnson infectious diseases and vaccines and global public health R&D global therapeutic area head Penny Heaton stated: “We are proud of this latest step in our years of work to ensure that some of the youngest people living with HIV have access to different treatment regimens that can work for them.
“If approved, this medicine could offer healthcare providers a new treatment option that ensures weight-appropriate dosing to better meet the needs of young people living with HIV.”
The latest development comes after Johnson & Johnson gained the global rights to Numab Therapeutics’ investigational first-in-class antibody, NM26 for atopic dermatitis.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.